NLTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NLTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Neoleukin Therapeutics's PEG is 1. Neoleukin Therapeutics's 5-Year TTM EBITDA Growth Rate is 5.11. Neoleukin Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-11.25. Therefore, the Peter Lynch Fair Value for today is $-57.47.
As of today (2024-10-31), Neoleukin Therapeutics's share price is $3.49. Neoleukin Therapeutics's Peter Lynch fair value is $-57.47. Therefore, Neoleukin Therapeutics's Price to Peter Lynch Fair Value Ratio for today is N/A.
The historical rank and industry rank for Neoleukin Therapeutics's Peter Lynch Fair Value or its related term are showing as below:
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
The historical data trend for Neoleukin Therapeutics's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neoleukin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Peter Lynch Fair Value | Get a 7-Day Free Trial | - | - | - | - | - |
Neoleukin Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Peter Lynch Fair Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Neoleukin Therapeutics's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Neoleukin Therapeutics's Price-to-Peter-Lynch-Fair-Value falls into.
Neoleukin Therapeutics's Peter Lynch Fair Value for today is calculated as
Peter Lynch Fair Value | = | PEG Ratio | * | 5-Year TTM EBITDA Growth Rate** | * | EPS without NRI (TTM) |
= | 1 | * | 5.11 | * | -11.247 | |
= | -57.47 |
Neoleukin Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Neoleukin Therapeutics (NAS:NLTX) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 5.11 instead of 15 in this case.
Neoleukin Therapeutics's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value | = | Share Price | / | Peter Lynch Fair Value |
= | 3.49 | / | -57.47 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Neoleukin Therapeutics's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Sean Michael Smith | officer: Principal Accounting Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Priti Patel | officer: Chief Medical Officer | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102 |
Erin Lavelle | director | C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Donna Cochener | officer: General Counsel, SVP Legal | C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102 |
Rohan Palekar | director | 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
Jonathan G Drachman | director, officer: See Remarks | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Carl Walkey | officer: Senior Vice President | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Robert Ho | officer: Chief Financial Officer | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Holly Vance | officer: General Counsel | C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102 |
Martin Babler | director | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Erin M. Lavelle | director | 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Jeremy Green | 10 percent owner | 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocus Research • 02-08-2024
By Business Wire • 07-25-2023
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By PRNewswire • 07-24-2023
By PRNewswire • 08-15-2023
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.